Clinical trials
Human Immunodeficiency Virus (HIV) Infection clinical trials
Below are recruiting human immunodeficiency virus (hiv) infection clinical trials, each written for real people, not researchers. We’re tracking 67 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07682961RecruitingPhase 3
Study of new HIV injection vs. standard injectables
This phase 3 trial tests a new long-acting, injectable two-drug combination (lenacapavir + teropavimab + zinlirvimab) vs. another injectable combo (cabotegravir + rilpivirine) for people whose HIV is already well-controlled on daily oral meds. It aims to see if the new combo can keep the virus under control with fewer injections.
Fort Lauderdale, FloridaAges 18 years+ - NCT07683000RecruitingPhase 3
Study of three HIV drugs for adults with controlled HIV
This trial tests a new combination of three medications, lenacapavir, teropavimab, and zinlirvimab, for people with HIV who currently have undetectable virus levels on a stable oral treatment. The goal is to see if these drugs can keep the virus suppressed, possibly allowing a simpler treatment plan.
Berkeley, MichiganAges 18 years+ - NCT05071079Recruiting
Study infects volunteers with a malaria germ to test treatment
This study gives healthy volunteers a controlled infection with a type of malaria (vivax) to see how the infection behaves and how well curative anti-malaria medicine works. It may help researchers better design and test future malaria vaccines and treatments.
BangkokAges 20–55 - NCT03258567RecruitingPhase 2
Nivolumab for EBV-related lymphomas and abnormal immune illnesses
This trial tests nivolumab (an immune therapy) for people with EBV-positive lymphoma or EBV-driven immune/lymph conditions. It may help shrink tumors or control the disease when standard treatments have not worked or are not suitable.
Bethesda, MarylandAges 12 years+ - NCT07525544RecruitingPhase 1
Safety Study of VH4770359 in Healthy Adults
This is an early-stage safety study testing a new investigational drug (VH4770359) in healthy volunteers. Researchers want to understand how the body processes the drug and ensure it is safe and well-tolerated.
Baltimore, MarylandAges 18–55 - NCT05674656RecruitingPhase 1/Phase 2
Testing dolutegravir and rilpivirine in HIV-positive children
This study checks how safe and well two HIV medicines work in children ages 6 to under 12. It also measures drug levels in the body to guide dosing and watch for side effects.
Long Beach, CaliforniaAges 6–12 - NCT07636928RecruitingPhase 1
Study of how the body absorbs a new HIV medicine
This early-stage study tests a new HIV medication (VH4524184) to understand how your body absorbs and processes it. You'll take a single dose of the medication with a small amount of radioactive tracer, which helps researchers track where the drug goes in your body.
GroningenAges 18–55 - NCT03351855RecruitingPhase 1/Phase 2
HPV immune cells (CTLs) for HPV treatment
This trial tests whether specially grown immune cells (HPV-CTLs) can fight HPV by targeting the virus. It is for people whose HPV infection has not responded to standard treatments.
Shenzhen, GuangdongAges 6 months–75 years - NCT03017820RecruitingPhase 1
Vaccine plus immune drugs for relapsed blood cancers
This early-phase trial tests a personalized-style vaccine (called VSV-hIFNβ-NIS) given alone or with other cancer-fighting medicines, including drugs that help the immune system attack. It is designed for people with certain relapsed or hard-to-treat multiple myeloma, acute myeloid leukemia, or lymphomas, to see if the treatment can shrink tumors and improve outcomes.
Scottsdale, ArizonaAges 18 years+ - NCT06223568RecruitingPhase 2
Chemo with or without a vaccine for HPV-related throat cancer
This trial tests whether adding an immunotherapy vaccine (PRGN-2009) to standard chemotherapy before surgery works better than chemotherapy alone for people with newly diagnosed HPV-positive oropharyngeal (head and neck) cancer.
Bethesda, MarylandAges 18–120 - NCT06508463RecruitingPhase 1
Viral therapy for peripheral T-cell lymphoma
This study tests an experimental virus therapy given through a vein for people with a type of lymphoma called peripheral T-cell lymphoma that has come back or not responded to treatment. The virus is designed to infect and destroy cancer cells. Some patients may also receive another drug called cemiplimab as part of a combination group.
Scottsdale, ArizonaAges 18 years+ - NCT06582654Recruiting
Antibody detection in first-void urine
This study looks at a new way to detect HPV antibodies in a urine sample. It is for people who have received the HPV vaccine to help improve testing.
Edegem, AntwerpAges 9–70 - NCT06874127Recruiting
Predicting liver repair in hepatitis B after treatment
This study looks at whether non-invasive tests can tell if liver damage is reversing in people with hepatitis B who have been on antiviral therapy for at least a year. It aims to help avoid repeated liver biopsies.
BeijingAges 18 years+ - NCT07510334RecruitingPhase 2
VSV Virus Plus Immunotherapy for Advanced Kidney Cancer
This trial tests a combination of a special virus (VSV-IFNβ-NIS) with two immunotherapy drugs (ipilimumab and nivolumab) for people with advanced clear cell kidney cancer that hasn't been treated yet. It aims to see if this approach helps shrink tumors or slow the disease.
Rochester, MinnesotaAges 18 years+ - NCT07006077RecruitingPhase 2
Investigational virus injection for advanced pancreatic cancer
This trial tests a new treatment that uses a virus to attack tumor cells directly. It is for people with advanced pancreatic cancer that has not responded to standard therapy. The virus is injected into a tumor, and the goal is to see if it can shrink the cancer or slow its growth.
Hangzhou, ZhejiangAges 18–75 - NCT07185243Recruiting
Study of virus injection plus immunotherapy for advanced solid tumors
This study tests a new combination treatment: a modified virus (hV01) injected directly into a tumor, plus a drug that helps your immune system attack cancer cells (PD-1 inhibitor). It is for people with advanced solid tumors that have not responded to standard therapies.
Xiamen, FujianAges 18–75 - NCT06980480RecruitingPhase 3
Gammagard to prevent infections in multiple myeloma
This study tests if adding Gammagard (a type of antibody therapy) to your multiple myeloma treatment with Tecvayli can help prevent serious infections. You may qualify if you recently started Tecvayli and are still responding to it.
Mobile, AlabamaAges 18 years+ - NCT05302271RecruitingPhase 1
Testing gene therapy for Friedreich’s ataxia heart disease
This Phase 1 trial tests an AAV gene therapy that aims to improve heart problems caused by Friedreich’s ataxia. You may be eligible if you have genetically confirmed Friedreich’s ataxia with measurable heart weakening but still enough heart function to safely receive treatment.
New York, New YorkAges 12–50 - NCT03266640RecruitingPhase 2
CMV cell therapy for difficult-to-treat viral infection
This trial tests an immune cell treatment (CMV-specific cytotoxic T cells) for people with a CMV infection that is not improving despite standard antivirals, or who cannot tolerate them. If eligible, the treatment aims to help the body control the virus after transplant-related immune problems.
Los Angeles, CaliforniaAges 1 month–79 years
Hear when a new Human Immunodeficiency Virus (HIV) Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for human immunodeficiency virus (hiv) infection?
- Yes. Clin2 currently lists 67 recruiting human immunodeficiency virus (hiv) infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a human immunodeficiency virus (hiv) infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a human immunodeficiency virus (hiv) infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.